Dimensional Fund Advisors
CTNM

Dimensional Fund Advisors’s Contineum Therapeutics CTNM Stock Holding History

Dimensional Fund Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.93M Buy
178,673
+118,727
+198% +$1.56M ﹤0.01% 2652
2026
Q1 		$782K Buy
+59,946
New +$804K ﹤0.01% 2883

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors's CTNM Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Contineum Therapeutics (CTNM) stake by 198% in Q2 2026, buying an estimated $1.56M and bringing the position to 178,673 shares worth $2.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2652.

Dimensional Fund Advisors first reported a position in CTNM in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Dimensional Fund Advisors held 178,673 shares of Contineum Therapeutics worth $2.93M as of Q2 2026.
  • Dimensional Fund Advisors bought 118,727 Contineum Therapeutics shares in Q2 2026, an estimated $1.56M.
  • Contineum Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2652 holding.
  • Dimensional Fund Advisors first reported a position in Contineum Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.